Association of Agent Orange and myeloproliferative neoplasms, thrombosis, and bleeding among veterans. Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with ...
Long-term efficacy and safety results published in Blood Advances continue to demonstrate the sustained survival benefit of adding TIBSOVO to azacitidine in IDH1-mutated AML Data support the use of ...
The addition of ivosidenib (Tibsovo) to azacitidine led to a threefold survival improvement for newly diagnosed IDH1-mutant acute myeloid leukemia (AML) patients who were ineligible for intensive ...
Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial. Findings from the phase 3 AGILE trial showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results